The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

The multimodal ArteraAI Prostate Test combines digital images of patients' biopsies and clinical data to predict prognoses and treatment outcomes.

The firm will use the funds to further develop its lead genetic medicine in Stargardt disease and advance its gene therapy pipeline in other indications.

NEW YORK – After Elevation Oncology faced several setbacks this year, its board has unanimously agreed to a buyout by Concentra Biosciences for $.36 per share plus a contingent value right for current ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.